On June 25, Insilico Medicine rose 5.64% in regular trading, trading at 44.88 HKD/share, with turnover of approximately 86.6 million HKD, extending its recent strong momentum.

On the news front, the company announced on June 22 a research collaboration with SK Biopharmaceuticals focused on AI-driven drug discovery for neuroimmunological diseases in the central nervous system. The potential total deal value exceeds $2.5 billion, encompassing development, regulatory, and commercialization milestone payments. Insilico Medicine is eligible to receive up to $18 million in upfront and near-term milestone payments, with additional single-digit percentage royalties on net sales post-commercialization. The positive sentiment from this partnership continues to ferment. Additionally, Southwest Securities published a research note highlighting that the company's lead pipeline asset Rentosertib has initiated Phase III clinical trials, noting that as the world's first drug candidate entirely discovered by generative AI to complete Phase IIa, its successful launch could represent a disruptive therapy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)